BioLife Solutions - BLFS Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1 year price targets for BioLife Solutions' shares. Their BLFS share price forecasts range from $29.00 to $34.00. On average, they predict the company's share price to reach $31.25 in the next year. This suggests a possible upside of 37.4% from the stock's current price.
View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts.

BioLife Solutions' stock was trading at $37.27 on January 1st, 2022. Since then, BLFS stock has decreased by 39.0% and is now trading at $22.75.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our BLFS earnings forecast.

BioLife Solutions, Inc. (NASDAQ:BLFS) announced its quarterly earnings data on Thursday, November, 11th. The medical equipment provider reported ($0.19) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.21. The medical equipment provider earned $33.80 million during the quarter, compared to analyst estimates of $31.65 million. BioLife Solutions had a negative trailing twelve-month return on equity of 7.54% and a negative net margin of 64.09%. During the same period in the previous year, the company earned ($0.02) EPS.

BioLife Solutions issued an update on its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $160.00 million-$166.00 million, compared to the consensus revenue estimate of $163.00 million.

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLFS stock can currently be purchased for approximately $22.75.

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $969.15 million and generates $119.16 million in revenue each year. The medical equipment provider earns $-7,640,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.

The company employs 432 workers across the globe.

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.